Mineral And Bone Disorder Treatment Market Size, Share & Trends Analysis Report By Product

 Focused on real-world business use, this report highlights what’s changing in the mineral and bone disorder treatment market and what companies should prepare for next.

 

 What Is The Current Outlook For The Mineral And Bone Disorder Treatment Market By 2025?
 The mineral and bone disorder treatment market size has grown strongly in recent years. It will grow from $3.3 billion in 2024 to $3.54 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to chronic kidney disease, aging population, rising awareness of mineral and bone disorders, increased availability of mineral and bone disorder treatments, rising disposable income levels.
 
 The mineral and bone disorder treatment market size is expected to see strong growth in the next few years. It will grow to $4.69 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to rising demand for quality of life treatments, growing demand for personalized medicine, government spending on healthcare, rising awareness of the importance of early diagnosis. Major trends in the forecast period include advancements in medical research, pharmaceutical developments, digital health, biologic therapies, telehealth and remote monitoring.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=12956&type=smp
 
 What Are The Key Driving Factors For The Growth Of The Mineral And Bone Disorder Treatment Market?
 The increased elderly population is expected to boost the growth of the mineral and bone disorder treatment market going forward. The elderly population is a demographic group defined as individuals who are 65 years old or older. Elderly people experience muscle and bone mass loss, leading to weakness and reduced strength. Mineral and bone treatment can help prevent age-related changes in muscles, bones and joints, strengthen bones and delay the pace of bone loss. For instance, in July 2024, according to the UK Parliament’s House of Commons Library, a UK-based government administration, in 2022, 12.7 million people in the UK, or 19% of the total population, will be aged 65 or older. By 2072, this figure is projected to rise to 22.1 million, making up 27% of the population. Therefore, the increased elderly population is driving the growth of the mineral and bone disorder treatment market. 
 
 Global Mineral And Bone Disorder Treatment Market Report Segmentation
 The mineral and bone disorder treatmentmarket covered in this report is segmented — 
 
 1) By Treatment: Diet; Nutrition; Medication; Supplements; Dialysis
 2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
 3) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
 
 Subsegments:
 1) By Diet: Calcium-Rich Foods; Vitamin D-Enriched Foods; Phosphorus-Rich Foods
 2) By Nutrition: Nutritional Counseling; Fortified Food Products; Meal Replacement Programs
 3) By Medication: Bisphosphonates; Hormonal Therapies; RANK Ligand Inhibitors
 4) By Supplements: Calcium Supplements; Vitamin D Supplements; Multivitamin Supplements
 5) By Dialysis: Hemodialysis; Peritoneal Dialysis; Continuous Renal Replacement Therapy (CRRT)
 
 What Are The Key Trends And Market Opportunities In The Mineral And Bone Disorder Treatment Sector?
 Major companies operating in the mineral and bone disorder treatment market are focusing on developing new products and getting them approved to strengthen their position in the market. Drug approval for mineral and bone is increasing due to the aging population and the increasing prevalence of chronic kidney diseases such as TYMLOS (abaloparatide), which contains the active drug abaloparatide, which is a synthetic (lab-made) form of the human parathyroid hormone. For instance, in December 2022, Radius Health Inc., a US-based biopharmaceutical company, received the approval for TYMLOS (abaloparatide), a parathyroid hormone-related peptide [PTHrP(1–34)] analog for the treatment to increase bone density in men with osteoporosis at high risk of fracture. It works as an anabolic agent for the bone by selectively activating the parathyroid hormone 1 receptor (PTH1R) expressed in osteoblasts and osteocytes, leading to increased bone formation and density.
 
 Who Are The Leading Players In The Mineral And Bone Disorder Treatment Market?
 Major companies operating in the mineral and bone disorder treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Co. Ltd., Eli Lilly And Company, Amgen Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., Mylan N.V., Daiichi Sankyo Company Limited, Servier Laboratories Pty Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Zydus Cadila Healthcare Ltd., Alembic Pharmaceuticals Limited, Ajanta Pharma Ltd., Abiogen Pharma Spa, Melinta Therapeutics Inc., Intas Pharmaceuticals Ltd., Radius Health Inc., EffRx Pharmaceuticals SA.
 
 View the full mineral and bone disorder treatment market report here:
 https://www.thebusinessresearchcompany.com/report/mineral-and-bone-disorder-treatment-global-market-report
 
 Which Region Is Projected To Hold The Largest Market Share In The Global Mineral And Bone Disorder Treatment Market By 2029?
 North America was the largest region in the mineral and bone disorder treatment market in 2024. The regions covered in mineral and bone disorder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company